IP Library Granted Patent US 11,389,370
Granted Patent B2
US 11,389,370 · App. 15/131,303 · Granted Jul 19, 2022

Treatments for blood sugar levels and muscle tissue optimization using extracorporeal acoustic shock waves

Inventor: John Warlick (Woodstock, GA)
Assignee: Softwave Tissue Regeneration Technologies, LLC
A61H23/008A61F5/41A61H19/30G10K15/043A61H2203/0468
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,389,370
App. No.
15/131,303
Granted
Jul 19, 2022
Kind
B2
Abstract

A method of treating red blood cells of a human patient has the steps of activating an acoustic shock wave generator or source to emit acoustic shock waves and subjecting a vascular system containing red blood cells and surrounding muscle tissue peripherally through an extremity of a patient to the acoustic shock waves by stimulating the extremity wherein the extremity is positioned within a path of the emitted shock waves and away from a geometric focal volume or point of the emitted shock waves. The methods also treat muscle tissue of aging patients, from muscle regeneration or athletes for legal performance enhancement without drugs.

Claims (12)

1. A method of lowering blood sugar level of a human patient exhibiting high blood sugar levels comprises the steps of:

measuring the human patient's blood sugar level prior to treating;

activating an acoustic shock wave generator or source to emit acoustic shock waves; and

subjecting a limb extremity of the human patient including a vascular system containing red blood cells and surrounding muscle tissue wherein the limb extremity is one of an arm, or a hand, or a leg, or a foot to the acoustic shock waves by stimulating through the limb extremity wherein the limb extremity of the human patient is positioned within a path of the emitted acoustic shock waves and away from a geometric focal volume or point of the emitted acoustic shock waves by emitting 500 or more shock waves at a low pulse energy of 0.1 mJ/mm 2 or higher up to 1.0 mJ/mm 2 to lower the patient's high blood sugar levels by emitting the acoustic shock waves through the limb extremity along a path through the skin and into muscle tissue, wherein the shock waves comprise amplitude above 0.1 MPa and rise times of the amplitude are below 100 nano-seconds with a duration of the acoustic shock waves being below 3 micro-seconds for a positive part of a cycle; and

measuring the patient's blood sugar level after the treatment wherein the human patient has an elevated baseline blood sugar level prior to treating the limb extremity which is lowered from the elevated baseline blood sugar level after treatment.

2. The method of lowering blood sugar level of a human patient of claim 1 , wherein the emitted acoustic shock waves are divergent or near planar.

3. The method of lowering blood sugar level of a human patient of claim 1 , wherein the emitted acoustic shock waves are convergent having a geometric focal volume or point at a distance of at least X from the acoustic shock wave generator or source, the method further comprising positioning the extremity at a distance less than the distance X from the generator or source.

4. The method of lowering blood sugar level of a human patient of claim 1 , wherein the patient is diabetic exhibiting type 1 or type 2 diabetes condition.

5. The method of lowering blood sugar level of a human patient of claim 1 wherein the limb extremity is a leg.

6. The method of lowering blood sugar level of a human patient of claim 5 , wherein the limb extremity is a foot.

7. The method of lowering blood sugar level of a human patient of claim 1 , wherein the limb extremity is an arm.

8. The method of lowering blood sugar level of a human patient of claim 1 , wherein repeating the treatment periodically a plurality of times over a period of weeks on the limb extremity to lower said baseline level of blood sugar.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2020
From: TISSUE REGENERATION TECHNOLOGIES, LLC
To: SOFTWAVE TISSUE REGENERATION TECHNOLOGIES, LLC
Reel/Frame 053946/0664 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2020
From: GENERAL PATENT, LLC
To: TISSUE REGENERATION TECHNOLOGIES, LLC
Reel/Frame 051659/0877 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2019
From: WARLICK, JOHN
To: GENERAL PATENT, LLC
Reel/Frame 050429/0950 →
Continuity (1)
Related Publication 20170296427A1 · Oct 19, 2017